We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Administration of Amyloid-β<sub>42</sub> Oligomer-Specific Monoclonal Antibody Improved Memory Performance in SAMP8 Mice.
- Authors
Ying Zhang; Jin-Sheng He; Xin Wang; Jun Wang; Fu-Xiang Bao; Si-Yuan Pang; Fan Yin; Hong-Gang Hu; Xiang-Lei Peng; Wei-Min Sun; Yan-Peng Zheng; Ling-Ling Hou; Tao Hong
- Abstract
Amyloid-β peptide (Aβ) is recognized by many as the leading cause of Alzheimer's disease (AD), and Aβ oligomers play a major role in the early-onset form of AD. Recently, the application of passive immunization targeting Aβ has been investigated as a potential method of AD immunotherapy. We used a strain of monoclonal antibody against Aβ42 oligomers, designated A8, as an Aβ inhibitor to suppress Aβ aggregation and Aβ-derived cell toxicity in vitro, and as a passive immunotherapy approach to treat SAMP8 (senescence accelerated mouse sub-line P8) mice, an animal model of AD, in vivo. First, our results showed that pre-incubation of A8 with Aβ oligomers inhibited both the maturation of Aβ fiber and Aβ oligomer toxicity on SH-SY5Y cells. Second, learning and memory was improved through intraperitoneal administration of A8 in SAMP8 mice. Third, Aβ pathology was ameliorated with decreased Aβ oligomers and phospho-tau levels in SAMP8 mice. Our data suggest that our monoclonal antibody A8 may be a candidate as a potential immunotherapeutic agent in AD.
- Subjects
AMYLOID beta-protein; MONOCLONAL antibodies; MEMORY; ALZHEIMER'S disease; OLIGOMERS; IMMUNOTHERAPY
- Publication
Journal of Alzheimer's Disease, 2011, Vol 23, Issue 3, p551
- ISSN
1387-2877
- Publication type
Article
- DOI
10.3233/JAD-2010-091195